Company news
Biotron Limited (ASX:BIT) news
Biotron Limited news releases on 6ix. Latest, Aug 27, 2021: Full Year Statutory Accounts and Preliminary Final Report
Press releases — page 2
Full Year Statutory Accounts and Preliminary Final Report
August 27, 2021
$1.4M R&D Tax Rebate
April 28, 2021
Appendix 4C - quarterly
April 28, 2021
Quarterly Cashflow Report
January 28, 2021
Biotron Compounds Show Activity Against SARS-CoV-2 Virus
September 6, 2020
Full Year Statutory Accounts
August 27, 2020
BIT225 Reverses HIV-Induced Immune Evasion
July 6, 2020
R&D Tax Refund Received
March 18, 2020
BIT225 RESTORES IMMUNE FUNCTION IN HIV-1 INFECTIONS
March 11, 2020
Biotron to Test its Compounds Against Coronavirus
February 5, 2020
Biotron Secures $5.1 Million Underwriting Agreement
November 8, 2019
Presentation to Investors
October 31, 2019
Appointment of International Advisory Board for BIT225
October 1, 2019
Presentation at BIO 2019
June 7, 2019
PRESENTATION OF BIT225-009 HIV-1 PHASE 2 DATA
November 28, 2018
Response to ASX aware letter
October 30, 2018
Biotron Secures $4.7 Million Underwriting Agreement
October 16, 2018
$1.07 million R&D Tax Incentive Received
October 14, 2018
Significant Immunological Outcomes in BIT225 HIV-1 Trial
September 28, 2018
Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial
August 7, 2018
Response to ASX Appendix 4C Query
May 10, 2018
Biotron Compounds Demonstrate Activity Against HBV
November 15, 2017
$1.6 Million R&D Tax Incentive Received
November 1, 2017
BIT225 Phase 2 HIV-1 Clinical Trial Update
June 15, 2017
$1.6 Million R&D Tax Rebate Received
February 12, 2017
BIT225 Accelerates HIV-1 Virus Reduction
February 6, 2017
Zika Virus Program Update
August 22, 2016
Biotron compounds demonstrate activity against Zika virus
May 23, 2016
$1.5 Million R&D Tax Rebate
April 20, 2016
Trading halt
March 30, 2016
Phase 2 Hepatitis C Trial Success
March 17, 2016
BIT225 MAY HAVE A BROADER ROLE IN LIMITING HIV-1 INFECTION
February 18, 2016
BIOTRON COMPOUNDS TESTED FOR ACTIVITY AGAINST ZIKA VIRUS
February 16, 2016
INTERIM HCV GENOTYPE 3 DATA FROM BIT225-008 STUDY
February 11, 2016
Annual Report to Shareholders
February 10, 2016